Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 765406, 6 pages
http://dx.doi.org/10.1155/2015/765406
Research Article

Are Thyroid Hormone and Tumor Cell Proliferation in Human Breast Cancers Positive for HER2 Associated?

1Department of Pharmacology, University of Athens, 75 Mikras Asias Avenue, Goudi, 11527 Athens, Greece
2Second Department of Internal Medicine, Hippokration Hospital, School of Medicine, University of Athens, 11527 Athens, Greece
3First Department of Medical Oncology, “Saint Savvas” Anticancer Hospital, 11522 Athens, Greece

Received 27 November 2014; Accepted 11 January 2015

Academic Editor: Alexander Schreiber

Copyright © 2015 Iordanis Mourouzis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Mourouzis, E. Politi, and C. Pantos, “Thyroid hormone and tissue repair: new tricks for an old hormone?” Journal of Thyroid Research, vol. 2013, Article ID 312104, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Casula and A. C. Bianco, “Thyroid hormone deiodinases and cancer,” Frontiers in Endocrinology, vol. 3, article 74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Pallud, M. Ramaugé, J.-M. Gavaret et al., “Regulation of type 3 iodothyronine deiodinase expression in cultured rat astrocytes: role of the Erk cascade,” Endocrinology, vol. 140, no. 6, pp. 2917–2923, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Pantos, C. Xinaris, I. Mourouzis et al., “Thyroid hormone receptor α1: a switch to cardiac cell ‘metamorphosis’?” Journal of Physiology and Pharmacology, vol. 59, no. 2, pp. 253–269, 2008. View at Google Scholar · View at Scopus
  5. M. D. Rosen and M. L. Privalsky, “Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis,” Journal of Thyroid Research, vol. 2011, Article ID 361304, 20 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Alexandros, M. Iordanis, Z. Athanasios, E. Konstantinos, L. Robert-William, and P. Constantinos, “Cell-type-dependent thyroid hormone effects on glioma tumor cell lines,” Journal of Thyroid Research, vol. 2011, Article ID 856050, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Zhang, Y. Chang, S. Ryu et al., “Thyroid hormones and mortality risk in euthyroid individuals: the Kangbuk Samsung health study,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, pp. 2467–2476, 2014. View at Publisher · View at Google Scholar
  8. G. T. Beatson, “On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases,” The Lancet, vol. 2, pp. 104–107, 1896. View at Google Scholar
  9. M. Cristofanilli, Y. Yamamura, S. W. Kau et al., “Thyroid hormone and breast carcinoma: primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma,” Cancer, vol. 103, no. 6, pp. 1122–1128, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. L. C. Moeller and D. Führer, “Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective,” Endocrine-Related Cancer, vol. 20, no. 2, pp. R19–R29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Simon, M.-T. C. Tang, L. Bernstein et al., “Do thyroid disorders increase the risk of breast cancer?” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 12, pp. 1574–1578, 2002. View at Google Scholar · View at Scopus
  12. S. Park, H. H. Jung, Y. H. Park, J. S. Ahn, and Y.-H. Im, “ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression,” Biochemical and Biophysical Research Communications, vol. 407, no. 4, pp. 680–686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Serra, M. Scaltriti, L. Prudkin et al., “PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer,” Oncogene, vol. 30, no. 22, pp. 2547–2557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Thrane, A. E. Lykkesfeldt, M. S. Larsen, B. S. Sorensen, and C. W. Yde, “Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling,” Breast Cancer Research and Treatment, vol. 139, no. 1, pp. 71–80, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Fallahi, S. M. Ferrari, R. Vita et al., “Thyroid dysfunctions induced by tyrosine kinase inhibitors,” Expert Opinion on Drug Safety, vol. 13, no. 6, pp. 723–733, 2014. View at Publisher · View at Google Scholar · View at Scopus